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ABSTRACT
Purpose: In the battle against cancer discovery of new and novel 
chemotherapeutic agent demands extreme obligation. Development of anticancer 
compounds with higher potency and reduced side-effects is timely and challenging.
Experimental Design: A small series of fourteen diastereomeric β-lactams (seven 
pairs) were synthesized through multi-step process exploring [2+2] ketene-imine 
cycloaddition as the key step. Comparative stereochemical preferences were studied 
through computational docking and validated by in vitro evaluation. β-tubulin was 
considered as possible molecular target and in vitro anticancer evaluation was 
conducted against SiHa, B16F10, K562 and Chang cell lines. Caspase-3 activation 
assay and hematoxylin/eosin staining of the cells were also accomplished. 
Results: Better docking scores of the cis- over the trans-β-lactams indicated 
favorable β-lactam—β-tubulin interactions in cis-geometry. In vitro (IC50) evaluation 
confirmed better anticancer activity of the cis-diastereoisomers. Apoptosis-induced 
cell death was supported by caspase-3 activation study. A cis-β-lactam [(±)-Cis-
3-amino-1-phenyl-4-(p-tolyl) azetidin-2-one, 6C] was found to be more active  
(in vitro) than the marketed natural drug colchicine against SiHa and B16F10 (six 
times higher potency) cell lines. Reduced toxicity (compared to colchicine) in Chang 
cells confirmed better site-selectivity (accordingly less side-effects) of 6C than 
colchicine. Aside from 6C, most of the reported molecules demonstrated good to 
strong in vitro anticancer activity against SiHa and B16F10 cancer cell lines. 
Conclusions: Stereochemical preferences of the cis-β-lactams over their trans-
counterparts, toward the molecular target β-tubulin, was confirmed by docking 
studies and in vitro anticancer evaluation. Apoptosis was identified as the cause of 
cell death. The lead 6C exhibited higher potency and selectivity than the marketed 
drug colchicine both in silico as well as in vitro.
INTRODUCTION
Cancer is one of the leading causes of death globally 
and is expected to increase approximately 70% in the next 
two decades [1]. Although cancer is not a new disease, 
the description of cancer is found in several ancient 
literatures since 3000 BC, yet it is one of the primary 
reasons of death till today and subsequently one of the 
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worse enemies of modern civilization. While radiotherapy, 
immunotherapy and surgical treatment play significant 
role in the battle against cancer but chemotherapy, either 
by own or in combination with other therapies, is still the 
most widely used strategy for the treatment of cancer. 
Moreover, several types of cancer have been developed 
drug resistance for which no effective drugs are available 
in the market [2, 3]. Therefore, it is important to develop 
new and selective anticancer drugs with higher potency 
and reduced side effects. 
Since the discovery of penicillin in 1928, the 
four-membered cyclic amide (frequently known as 
2-azetidinone or β-lactam) possesses the central position 
in drug discovery research, in particular, to treat a wide 
range of microbial infection. Notably, the β-lactam 
pharmacophore is present in a huge number of molecules 
(both natural and synthetic) that dominate worldwide the 
market of antibiotics [4–6]. In contrary, many compounds 
(natural, synthetic or semi-synthetic) are being used in 
cancer chemotherapy but the use of β-lactam derivatives in 
cancer chemotherapy is still unknown. This might be due 
to the reason that the research on β-lactam as anticancer 
agents is comparatively new and not been broadly 
explored. In fact, the anticancer activity of diversely 
substituted trans-β-lactams have been reported [7–15] to 
some extent and after careful search of available literatures 
we did not find a single example targeted to comparative 
computational and biological studies of anticancer 
potential of cis- and trans-β-lactams. To the best of our 
knowledge, this is the first report that systematically 
correlates the diastereoselectivity (cis- and trans-) of 
β-lactams with anticancer activity. 
RESULTS
Chemistry
In the present study Staudinger [2+2] ketene-imine 
cycloaddition reaction [16] was performed extensively 
for the diastereomeric synthesis of diversely substituted 
3-phthalimido β-lactams. In the subsequent step, the 
deprotection of the primary amine was carried out by 
converting the 3-phthalimido β-lactams to 3-amino-
azetidin-2-ones with ethylene diamine in dry ethanol 
(Scheme 1). 
A total of 14 β-lactam derivatives (seven pairs of 
diastereomers) have been synthesized (Supplementary 
Table 1) through multi-step process (Scheme 1) exploring 
[2+2] ketene-imine cycloaddition as the key step. Although 
the compounds were synthesized through multi-step process 
and purified by repeated column chromatography yet good 
to excellent yields were isolated each cases. The structure 
and druglikeness of each molecule are shown in Table 1.
The structure of the 2-azetidinone derivatives were 
elucidated by extensive spectroscopic analyses as follows:
(±)-Cis-3-amino-1,4-bis(4-methoxyphenyl) azetidin-
2-one (1C). Brown solid (78%); Formula Weight: 298.34; 
MP 102 ºC; IR (KBr) 3401, 3012, 1715,1507, 1246, 826 
cm-1; 1H NMR (600 MHz, CDCl3) δ 7.32 (d, 2H), 7.20 (d, 
2H), 6.95 (d, 2H), 6.81 (d, 2H), 5.21 (d, J = 5.0 Hz, 1H), 
4.57 (d, J = 5.0 Hz, 1H), 3.82 (s, 3H), 3.77 (s, 3H). Formula: 
C16H16N2O2; Anal. calcd for: C, 71.6%; H, 6.0%; N, 10.4%.
(±)-Cis-3-amino-4-(4-methoxyphenyl)-1-phenyl-
azetidin-2-one (2C). Brown solid (88%); Formula Weight: 
268.32; MP 106 ºC; IR (KBr) 3341, 2928,1728, 1499, 
1248, 746 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.29 – 7.08 
(m, 2H), 7.03 – 6.93 (m, 2H), 6.86 – 6.77 (m, 4H), 4.56 
(d, J = 2.2 Hz, 1H), 3.96 (d, J = 2.3 Hz, 1H), 3.71 (s, 3H) 
1.93 (s,2H). Anal. calcd for: C17H18N2O3 Composition: C, 
68.4%; H, 6.1%; N, 9.4%.
(±)-Cis-3-amino-4-(3,4-dimethoxyphenyl)-1-(4-
methoxyphenyl) azetidin-2-one (3C). Brown solid (68%); 
Formula Weight: 328.36; MP 92 ºC; IR (KBr) 3379, 2956, 
1738, 1509,1237, 828 cm-1; 1H NMR (600 MHz, CDCl3) 
δ 6.83 – 6.80 (m, 2H), 6.79 – 6.76 (m, 4H), 6.75 – 6.74 
(m, 9H), , 5.10 (d, J = 5.4 Hz, 1H), 4.48 (d, J = 5.4 Hz, 
1H), 3.80 - 3.68 (m, 9H). Anal. calcd for: C18H20N2O4; 
Composition: C, 65.8%; H, 6.1%; N, 8.5%. 
Scheme 1: Diastereoselective synthesis of β-lactams via [2+2] ketene-imine cycloaddition reaction.
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(±)-Cis-3-amino-1-(4-methoxyphenyl)-4-(2-
nitrophenyl) azetidin-2-one (4C). Brown solid (52%); 
Formula Weight: 313.31; MP 185 ºC; IR (KBr) 3325, 2952, 
1747, 1509, 1248, 822 cm-1; 1H NMR (600 MHz, CDCl3) δ 
8.08 – 8.03 (m, 3H), 7.79 – 7.76 (m, 3H), 7.75 – 7.70 (m, 
1H), 7.70 – 7.66 (m, 6H), 7.62 – 7.56 (m, 6H), 6.08 (d, 
J = 5.8 Hz, 5H), 6.05 (d, J = 5.8 Hz, 5H), 5.35 – 5.27 
(m, 1H), 3.83 (s, 3H). Anal. calcd for: C16H15N3O4; 
Composition: C 61.3%, H 4.8%, N 13.4%. 
(±)-Cis-3-amino-1-(4-methoxyphenyl)-4-(p-tolyl) 
azetidin-2-one (5C). Brown solid (80%); Formula Weight: 
282.34; MP 103 ºC; IR (KBr)3359, 2934, 1730, 1510, 1245, 
823 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.24 – 7.20 (m, 
6H), 7.14 (d, J = 8.1 Hz, 3H), 7.07 (d, J = 8.1 Hz, 1H), 
6.74 – 6.70 (m, 7H), 5.13 (d, J = 5.4 Hz, 3H), 4.50 (d, 
J = 5.5 Hz, 3H), 3.68 (s, 3H) 2.36 – 2.32 (m, 3H). Anal. calcd 
for: C17H18N2O2; Composition: C, 72.3%; H, 6.4%; N, 9.9%. 
(±)-Cis-3-amino-1-phenyl-4-(p-tolyl) azetidin-2-
one (6C). Brown solid (84%); Formula Weight: 252.31; 
MP 130 ºC; IR (KBr) 3356, 2925, 1731, 1502, 748 cm-1; 
1H NMR (600 MHz, CDCl3) δ 7.73 (dt, J = 13.6, 6.9 Hz, 
2H), 7.71 – 7.65 (m, 2H), 7.43 – 7.35 (m, 2H), 7.26 (ddd, 
J = 8.1, 5.0, 2.4 Hz, 2H), 6.94 – 6.87 (m, 4H), 5.68 (d, 
J = 5.5 Hz, 1H), 5.46 (d, J = 5.5 Hz, 1H), 3.82 (s, 3H). 
Anal. calcd for: C16H16N2O; Composition: C, 76.2%; H, 
6.4%; N, 11.1%. 
(±)-Cis-3-amino-1-(4-methoxyphenyl)-4-(2-pyridyl)
azetidin-2-one (7C). Brown solid (51%); Formula Weight: 
269.30; MP 120 ºC; IR (KBr) 3373, 2952, 1721, 1509, 
1239, 828 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.71 (d, 
J = 4.0 Hz, 3H), 7.74 (td, J = 7.7, 1.6 Hz, 3H), 7.33 (d, 
J = 7.7 Hz, 4H), 7.31 – 7.27 (m, 13H), 6.82 (d, J = 9.1 Hz, 
6H), 5.32 (d, J = 5.4 Hz, 3H), 4.76 (d, J = 5.5 Hz, 3H), 
3.77 (s, 3H). Anal. calcd for: C
15
H
15
N3O2; Composition: C, 
66.9%; H, 5.6%; N, 15.6%.
(±)-Trans-3-amino-1,4-bis(4-methoxyphenyl) 
azetidin-2-one (1T). Brown solid (71%); Formula Weight: 
268.32; MP 96 ºC; IR (KBr) 3341, 2953, 1724,1510, 1245, 
823 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.19 (d, 2H), 7.14 
(d, 2H), 6.81 (d, 2H), 6.69 (d, 2H), 4.57 (d, J = 1.6 Hz, 
1H), 3.96 (d, J = 1.7 Hz, 1H), 3.72 (s, 3H), 3.66 (s, 3H). 
Anal. calcd for: C16H16N2O2; Composition: C, 71.6%; H, 
6.0%; N, 10.4%.
(±)-Trans-3-amino-4-(4-methoxyphenyl)-1-phenyl-
azetidin-2-one (2T). Brown solid (72%); Formula Weight: 
298.34; MP 102 ºC; IR (KBr) 3342, 3065,1730, 1513, 1249, 
747 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.29 – 7.08 (m, 
4H), 7.03 (t, 1H), 6.86 (d, 4H), 4.56 (d, J = 2.2 Hz, 1H), 3.96 
(d, J = 2.3 Hz, 1H), 3.71 (s, 3H) 1.84 (s,2H). Anal. calcd 
for: C17H18N2O3Composition: C, 68.4%; H, 6.1%; N, 9.4%. 
(±)-Trans-3-amino-4-(3,4-dimethoxyphenyl)-1-(4-
methoxyphenyl) azetidin-2-one (3T). Brown solid (93%); 
Formula Weight: 328.36; MP 104 ºC; IR (KBr) 3301, 3001, 
1733, 1508,1237, 877 cm-1; 1H NMR (600 MHz, CDCl3) δ 
7.32 (d, 13H), 7.25 (d, 9H), 6.91 (d, 12H), 6.87 (d, 6H), 6.85 – 
6.83 (m, 10H), 6.81 (d,13H), 6.76 (s, 1H), 4.61 (d, J = 1.7 Hz, 
5H), 4.07 (d, J = 1.7 Hz, 7H), 3.89 – 3.77 (m, 9H). Anal. calcd 
for: C18H20N2O4; Composition: C, 65.8%; H, 6.1%; N, 8.5%.
(±)-Trans-3-amino-1-(4-methoxyphenyl)-4-(2-
nitrophenyl) azetidin-2-one (4T). Brown solid (28%); 
Formula Weight: 313.31; MP 195 ºC;IR (KBr) 3282, 3064, 
1745, 1509, 1243, 860 cm-1; 1H NMR (600 MHz, CDCl3) δ 
Table 1: Molecular docking of the β-lactam derivatives on the binding sites of the β-tubulin
Code
Docking score (kcal/mol)
Colchicine site
Docking score (kcal/mol) Taxol 
site
Docking score (kcal/mol)
Vinca site
1C −6.6 −6.7 −6.7
2C −7.0 −6.4 −6.1
3C −6.8 −6.4 −6.2
4C −7.2 −6.3 −6.8
5C −7.2 −6.7 −6.7
6C −7.6 −7.0 −6.9
7C −6.5 −6.2 −6.0
1T −6.6 −6.7 −6.6
2T −7.2 −6.7 −6.9
3T −6.8 −6.6 −6.6
4T −7.3 −6.9 −6.9
5T −7.4 −6.9 −7.3
6T −7.4 −6.8 −7.0
7T −6.7 −6.3 −6.5
Colchicine −7.4 --- ---
Paclitaxel --- −9.8 ---
Vinblastine --- --- −10.0
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7.17 – 7.13 (m, 6H), 7.09 (d, J = 7.7 Hz, 7H), 6.72 – 6.67 
(m, 3H), 4.89 (s, 6H), 4.84 (d, J = 2.0 Hz, 3H), 4.55 (d, 
J = 2.0 Hz, 1H), 3.66 (s, 3H). Anal. calcd for: C16H15N3O4; 
Composition: C 61.3%, H 4.8%, N 13.4%. 
(±)-Trans-3-amino-1-(4-methoxyphenyl)-4-(p-tolyl)
azetidin-2-one (5T). Brown solid (95%); Formula Weight: 
282.34; MP 110 ºC; IR (KBr) 3294, 2952, 1730, 1509, 1242, 
824 cm-1; 1H NMR (600 MHz, CDCl3) δ 7.23 – 7.18 (m, 6H), 
7.15 (m, 2H), 7.10 (d, J = 7.9 Hz, 13H), 7.06 (d, J = 8.1 Hz, 
3H), 6.74 – 6.68 (m, 1H), 4.52 (d, J = 2.1 Hz, 1H), 3.93 (d, 
J = 2.1 Hz, 1H), 3.66 (s, 3H) 2.36 – 2.32 (m, 3H). Anal. calcd 
for: C17H18N2O2; Composition: C, 72.3%; H 6.4%; N, 9.9%.
(±)-Trans-3-amino-1-phenyl-4-(p-tolyl)azetidin-2-
one (6T). Brown solid (62%); Formula Weight: 252.31; 
MP 135 ºC; IR (KBr) 3354, 3028, 1731, 1501, 792 cm-1; 
1H NMR (600 MHz, CDCl3) δ 7.21 (dt, J = 11.6, 3.1 Hz, 
2H), 7.18 – 7.14 (m, 4H), 7.11 (d, J = 7.9 Hz, 2H), 7.00 
– 6.94 (m, 1H), 4.57 (d, J = 2.2 Hz, 1H), 3.96 (d, J = 2.3 
Hz, 1H), 2.32 – 2.23 (m, 3H), 1.78 (s, 3H). Anal. calcd for: 
C16H16N2O; Composition: C, 76.2%; H, 6.4%; N, 11.1%.
(±)-Trans-3-amino-1-(4-methoxyphenyl)-4-(2-
pyridyl)azetidin-2-one (7T). Brown solid (60%);Formula 
Weight: 269.30; MP 114 ºC;IR (KBr) 3371, 2953, 1729, 
1510, 1294, 820 cm-1; 1H NMR (600 MHz, CDCl3) δ 8.71 
(d, J = 4.0 Hz, 3H), 7.74 (td, J = 7.7, 1.6 Hz, 3H), 7.33 (d, 
J = 7.7 Hz, 4H), 7.31 – 7.27 (m, 13H), 6.82 (d, J = 9.1 Hz, 
6H), 5.32 (d, J = 2.3 Hz, 3H), 4.76 (d, J = 2.3 Hz, 3H), 
3.77 (s, 3H). Anal. calcd for: C
15
H
15
N3O2; Composition: C, 
66.9%; H, 5.6%; N, 15.6%.
Molecular docking 
By means of computational chemistry, a molecular 
docking assay was performed targeting the protein 
β-tubulin. The drug-protein interaction of all the 
fourteen 3-amino-azetidin-2-one derivatives (1C–7C and 
1T–7T) was studied on the three available and known 
binding sites (vinca, taxol and colchicine) of β-tubulin 
[17]. Vinblastine, taxol (paclitaxel) and colchicine were 
considered as the control molecules and the free energy 
(Kcal/mol) for each compound was calculated (Table 1). 
The docking interactions of (±)-Cis-3-amino-1-
phenyl-4-(p-tolyl)azetidin-one (6C) is shown in Figure 1. 
Cytotoxic activity
The IC
50
 values of the fourteen 2-azetidinone 
derivatives (seven pair of diastereomers) were calculated 
from the concentrations of 10 to 0.312 µM for each 
compound (triplicate) against SiHa (human cervical), 
B16F10 (murine melanoma), K562 (human immortalized 
myelogenous leukemia) and Chang cell lines. IC
50
 values 
of the azetidin-2-ones are shown in Table 2.
The cytotoxic effect of the compound 6C in 
SiHa and Chang cells has been studied (Figure 2). In a 
Hematoxylin/Eosin staining sample where monolayers 
of SiHa (a) and Chang (d) cells in the untreated control 
groups (negative control) showed the characteristic 
morphology of normal cell cultures, irregularly shaped, 
well-defined junctions and nucleus-cytoplasm ratio 
was preserved. In SiHa cells incubated with 1 µM of 
the compound 6C (b) morphological alterations was 
observed; mainly characterized by loss of cytoplasm 
and decrease in the size of nuclei (arrows). Moreover, 
in the incubated Chang cells, 1 µM concentration of the 
compound 6C (e), the damage could be characterized by 
the appearance of multiple intracytoplasmic vacuoles 
(*). Treatment with taxol (20 mg/mL) induced severe 
Figure 1: Molecular docking of the compound 6C on β-tubulin molecule.
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cell damage in SiHa cells (c), where nuclear membrane 
pucker (creaser) (n), perinuclear vacuoles (pv), loss 
of cytoplasm (arrows) and nuclear picnosis (p) were 
observed. On the other hand, Chang cells (f) experienced 
early apoptosis, was indicated by protrusions of the 
cell membrane (membrane blebbing) (arrowhead), 
cytoplasmic vacuoles (arrows) and sporadically large 
perinuclear vacuoles (pv). The morphological studies 
clearly demonstrated different susceptibility between 
SiHa and Chang cells to the identical treatment as well as 
different mechanism of cell damage for the investigative 
compound as well as taxol in SiHa and Chang cell lines 
although both the compounds (6C and taxol) ruptured the 
cellular monolayer. 
Figure 2: Cytotoxic effect of the compound 6C in SiHa and Chang cells.
Table 2: IC
50
 values (µM) of β-lactam derivatives against SiHa, B16F10, K562 and Chang cell lines 
(triplicate)
Compound code SiHa B16F10 K562 Chang
1T 7.17 ± 0.3 5.16 ± 0.5 > 10.00 7.91 ± 0.4
2T 7.14 ± 0.5 7.63 ± 0.4 > 10.00 > 10.00
3T > 10.00 > 10.00 > 10.00 > 10.00
4T 8.12 ± 0.4 > 10.00 > 10.00 > 10.00
5T 7.79 ± 0.5 7.14 ± 0.6 > 10.00 > 10.00
6T 4.79 ± 0.6 5.79 ± 0.4 > 10.00 > 10.00
7T > 10.00 > 10.00 > 10.00 > 10.00
1C 4.21 ± 0.4 3.33 ± 0.3 > 10.00 6.21 ± 0.5
2C 6.20 ± 0.6 1.71 ± 0.3 > 10.00 8.03 ± 0.5
3C 5.10 ± 0.4 3.91 ± 0.3 6.14 ± 0.4 9.32 ± 0.6
4C 7.28 ± 0.5 5.91 ± 0.6 > 10.00 7.37 ± 0.4
5C 4.03 ± 0.5 2.09 ± 0.1 > 10.00 7.01 ± 0.1
6C 2.34 ± 0.2 0.70 ± 0.1 > 10.00 6.89 ± 0.3
7C 8.43 ± 0.3 > 10.00 6.86 ± 0.4 5.49 ± 0.4
Colchicine 2.5 ± 0.5 4.1 ± 0.1 1.3 ± 0.1 0.52 ± 0.1
Paclitaxel 364 ± 310* 9.57 ± 0.2 4.80 ± 0.4* 0.068 ± 0.02
Vinblastine 10.88 ± 0.8 55 ± 28* 0.006 ± 0.0 ND**
*ng/mL; **Not determined.
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Alternatively, the trans diastereomers exhibited 
moderate to poor (IC
50
: 4.79 to >10.00 in SiHa and 5.16 to 
> 10.00 in B16F10 cell lines) anticancer activity against 
the tested cancer cell lines as well as in Chang (normal 
liver) cells (Table 2).
Apoptotic activity 
The cis-diastereomer 6C demonstrated apoptosis 
in B16F10 cancer cells through caspase-3 activation, was 
determined by choosing podophyllotoxin (a γ-lactone 
bearing pyrogallol derivative) as positive control (Figure 3).
DISCUSSION
It is always challenging to control the 
diastereoselectivity in β-lactam synthesis. The cis and trans 
diastereomers can be identified by the coupling constant 
values of the protons H-3 and H-4 in the β-lactam ring 
(J3,4 > 4.0 Hz represents a cis isomer whereas J3,4 < 3.0 
Hz indicates trans stereoisomer) [18]. As a representative 
example the 1H NMR spectra of the compounds (±)-trans-
3-amino-1,4-bis(4-methoxyphenyl)azetidin-2-one (1T) and 
(±)-cis-3-amino-1,4-bis(4-methoxyphenyl)azetidin-2-one 
(1C) could be considered (Figure 4). For the compound 
(1T) the two protons H-3 and H-4 appeared at 3.96 ppm 
(J = 1.7 Hz) and 4.57 ppm (J = 1.6 Hz) respectively whereas 
in the compound (1C), the coupling constant values for both 
the protons H-3 and H-4 are the same (J = 5.0 Hz). In fact, 
the diastereoselectivity in β-lactam formation depends on 
the generation of zwitterionic intermediate and the extent of 
conrotatory cyclization (ring-closure) of the intermediate to 
produce cis or trans β lactams [19, 20]. 
It is well-known that stereochemistry of a drug 
molecule is greatly responsible for its pharmacological 
activity. Accordingly, the stereoisomer that produces better 
Figure 3: B16F10 cells under conditions of apoptosis with podophyllotoxin and 6C. (A) Control untreated cells, (B) Cells 
treated with podophyllotoxin, (C) Cells treated with the compound 6C.
Figure 4: 1H NMR spectra of 1C (Left) and 1T (Right).
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therapeutic activity is known as eutomer and the less potent 
(sometimes inactive or even toxic) stereoisomer is known 
as distomer. The drugability of the newly synthesized 
terminal β-lactams (1C–1T and 1T–7T) has been validated 
by modified ‘Rule of 5’ (RO5) in Supplementary Table 1. 
It was found that all the fourteen newly synthesized β-lactams 
possess durglikeness and consequently can be termed as 
possible ‘hits’. The in vitro anticancer evaluation has been 
carried out against SiHa (human cervical carcinoma), 
B16F10 (murine melanoma), K562 (human immortalized 
myelogenous leukemia) and Chang cell lines. It has also 
been confirmed that the mechanism of anticancer activity was 
apoptosis-induced cell death. Finally, through a molecular 
docking analysis, a better and clearer understanding of the 
plausible β-lactam–β-tubulin interaction was explained, 
considering the protein β-tubulin as the therapeutic target. 
The free energy coupling values for the cis and trans 
β-lactams on the proposed target β-tubulin do not match 
with that of two widely used natural anticancer drugs 
taxol and vincristine rather the values match with that of 
another anticancer alkaloid colchicine. This indicates that 
the binding sites of the β-lactams and colchicine are similar 
in nature. Accordingly, the detail mechanism of action of 
the β-lactams might be similar to that of colchicine. The 
docking score of the compound 6C is better than the natural 
drug colchicine (-7.6 compared to -7.4 for colchicine, Table 
1) supports better anticancer activity of this compound than 
colchicine which has been confirmed by in vitro anticancer 
evaluation (Table 2). The IC
50
 values of the compound 6C 
are better than colchicine against SiHa and B16F10 cancer 
cell lines. In fact, the drug-protein interactions depend on the 
chemical nature and three dimensional spatial orientation of 
the drug molecule and the subsequent interactions with the 
amino acid residues on the binding sites in β-tubulin. The 
molecular interactions of the compound 6C with β-tubulin 
showed bonding interactions with the Cys 239, Lys 252, Val 
323, Met 257, Lys 350, Leu 246 and Ala 248 amino acid 
residues (Figure 1). Based on the accumulated data a strong 
interaction between the β-lactam pharmacophore and the 
aminoacid residues of the β-tubulin can be proposed. 
Interestingly, the compound 6C showed strong 
in vitro anticancer activity (IC
50 
= 0.7 µM) in murine 
melanoma (B16F10) cell lines and IC
50 
= 2.34 µM in 
human cervical carcinoma SiHa cell lines and qualified 
as the lead with considerable anticancer activity in 
comparison to colchicine. The trans-β-lactams 1T, 2T, 
4T, 5T, and the cis-β-lactams 2C, 3C, 4C and 7C showed 
good in vitro anticancer activity (IC
50 
= 5 – 10 µM) against 
SiHa cancer cell lines whereas the β-lactams 1T, 2T, 5T 
and 4C demonstrated good in vitro anticancer activity 
(IC
50 
= 5 –10 µM) against B16F10 cancer cell lines. On 
the other hand, two compounds 2C and 3C showed strong 
in vitro anticancer activity (IC
50
 < 5 µM) against B16F10 
cancer cell lines. Besides the lead compound 6C, two 
other compounds 1C and 5C demonstrated strong in vitro 
anticancer activity (IC
50 
= 5–10 µM) against SiHa and 
B16F10 cancer cell lines. Interestingly, two cis-compounds 
3C and 7C showed good in vitro anticancer activity (IC
50 
= 
5–10 µM) against K562 cancer cell lines. All the fourteen 
compounds are less toxic (more selective) than the positive 
control colchicine, a well-known cancer chemotherapeutic 
agent. In Chang cells 6C showed 10 times lesser toxicity in 
comparison to the drug colchicine (Table 2). 
MATERIALS AND METHODS 
Chemistry
Melting points were determined in a Fisher 
Scientific electrochemical Mel-Temp* manual melting 
point apparatus (Model 1001) equipped with a 300ºC 
thermometer. FT-IR spectra were recorded on a Bruker 
Alpha modular Platinum-ATR FT-IR spectrometer with 
OPUS software, using the samples directly (neat) without 
making pallets. 1H NMR (600 MHz) and 13C NMR 
(150 MHz) spectra were obtained at room temperature 
with Bruker superconducting Ultrashield Plus 600 
MHz NMR spectrometer with central field 14.09 T, 
coil inductance 89.1 H, and magnetic energy 1127.2 kJ 
using CDCl3 as solvent. All the solvents were purchased 
from Fisher-Scientific throughout the investigation. 
Dichloromethane and triethylamine were dried following 
the standard procedures. Deionized water was used for the 
preparation of all aqueous solutions. 
General procedure for the synthesis of imines
Amine and aldehyde were mixed in equimolar (1:1) 
ratio and refluxed in dry toluene using a Dean-Stark water 
separator. After completion of the reaction (monitored by 
thin layer chromatography, 2–3 hours), the solvent was 
removed under reduced pressure distillation (by rotavapor) 
and the pure imine was isolated by crystallization from 
dichloromethane/hexanes. 
General procedure for the synthesis of 
3-phthalimido β-lactams via the Staudinger 
reaction
A representative experimental procedure is 
described as follows: A solution of phthalimidoacetic 
acid (N-phthaloylglycine) (1.5 mmol) in anhydrous 
dichloromethane (10 mL) was added (dropwise during 
30 minutes) to another solution consisted of 2-chloro-1-
methylpyridinium iodide (Mukaiyama reagent, 3 mmol) 
and triethylamine (6 mmol) in 10 mL dry dichloromethane 
at 0 to (–5)°C temperature under inert (argon) atmosphere. 
This mixture was stirred for 2 hours maintaining the same 
temperature. Imine (1 mmol) in dry dichloromethane (10 
mL) was then added to this mixture at the same temperature. 
The reaction mixture was then stirred overnight at room 
temperature and monitored by thin layer chromatography 
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(TLC). After completion of the reaction, the reaction 
mixture was washed with saturated sodium bicarbonate 
solution (10 mL), brine (10 mL) and deionized water 
successively. The organic layer was dried over anhydrous 
sodium sulfate, filtered and evaporated to obtain the crude 
product. Column chromatography over silica gel was 
performed using ethyl acetate/hexanes mixtures to isolate 
the cis- and trans-3-phthalimido β-lactams in pure form. 
The cis:trans ratio was approximately 2:1 in all the cases. 
General procedure for the synthesis of 3-amino 
β-lactams from 3-phthalimido β-lactam
Ethylenediamine (2 mmol) was added to a solution 
of diastereomerically pure 3-phthalimido β-lactam 
(1 mmol) in anhydrous ethyl alcohol (5 mL) under argon 
atmosphere. This mixture was stirred at room temperature 
and the progress of the reaction was monitored by TLC. 
After completion of the reaction (15 min–1 h) the ethanol 
was removed by reduced pressure distillation and the crude 
mass was extracted with ethyl acetate (25 mL). The ethyl 
acetate layer was washed with brine and water successively 
(10 mL), and dried over anhydrous sodium sulfate. The pure 
products were obtained via column chromatography over 
silica gel using ethyl acetate/hexanes as the eluent. 
Molecular docking
One of the major cancer related proteins, β-tubulin, 
was considered as the theoretical target to perform docking 
studies of the azetidin-2-ones (β-lactams) as possible 
antiproliferative compounds. The hydrogens and charges 
on receptor and ligand were assigned with the Chimera 
program [21]. The pdbqt files for docking simulations 
were generated using the AutoDock Tools interface. The 
docking of azetidine-2-one derivatives on β-tubulin was 
performed with Autodock 4.2 program [22]. The grid sizes 
in each dimension (x, y, and z) were 60 Å, grid points 
separated by 0.375 Å, with its center in 116, 89 and 6 
for x, y and z, respectively. The analysis of AutoDock 
predicted molecular interactions was conducted by 
AutoDock vina interface and Chimera program. Maestro 
software showed the key amino acids from colchicine 
binding site of β-tubulin.
Biology
Cytotoxic activity 
In vitro anticancer assays were performed in 
triplicate for the determination of mean values. The human 
cervical carcinoma SiHa, murine melanoma B16F10, 
chronic myelogenous leukemia (CML) K562, and Chang 
cell lines were cultured in minimum essential medium 
of Eagle at 37 °C in a 95% O2/5% CO2 atmosphere 
with 10% fetal bovine serum, 2 mM L-glutamine and 
1% penicillin/streptomycin. Cells were trypsinized and 
seeded at a density of 5 × 104 cells/mL in a 96-well plate 
and incubated at 37 °C, 95% O2/5% CO2 atmosphere for 
24 h. Thereafter the cells were treated with azetidin-2-one 
derivatives (dissolved in DMSO) at various concentrations 
between 312 nM–10 µM, and re-incubated for further 72 h. 
Wells containing the equal volume of the vehicle DMSO 
(1% v/v) were used as background (negative control). The 
culture medium was then removed and the cells washed 
with 100 µL phosphate buffered saline (PBS); then 10 µL 
WST-1 (Roche, USA) was added. Cells were incubated for 
2 h in absence of light at 37°C, and absorbance was read 
subsequently [23]. The absorbance value of cells without 
added compound was set to 100% cell viability and was 
compared versus cell death density (cells treated with 
Triton ×100) and also natural anticancer drug colchicine as 
positive control compound. Afterwards, these values were 
used to assess half maximal inhibitory concentration (IC
50
) 
using Graph-Pad Prism software.
Hematoxylin/Eosin staining of the cells
Cells (10 × 104) were grown on coated poly-lysine 
coverslips which were placed in 6-well microplates 
overnight and then incubated for 24 h in the presence 
of compound 6C or taxol, subsequently stained with 
hematoxylin and eosin. Coverslips were then observed by 
Light microscopy of bright field (40X).
Apoptotic activity
The mechanism of cell death was identified as 
apoptosis. It was validated with the compound 6C. 
Enzyme activity associated with the induction of 
apoptosis was determined by caspase-3 assay (Invitrogen, 
USA) as described in the protocol [24]. A concentration 
of approximately 3 × 106 cells/mL (B16F10) was taken 
and incubated for 24 h at 37 °C in 5% CO2 environment. 
Podophyllotoxin (apoptosis inducing agent) was used 
as positive control. After incubation for 24 h the cells 
were re-suspended and 50 µL of cell lysis reagent was 
added, then cells were incubated for 10 min in ice bath 
and centrifuged. The supernatant (cytosol extract) was 
transferred into a new effendrof. Cytosol extract was 
diluted with cell lysis reagent to a concentration of 
2 µg/µL, in a total volume of 50 µL. Then 50 µL of 2X 
reaction buffer and 5 µL of tetrapeptide-p-nitroaniline 
(DEVD-pNA) were added. It was incubated at 37 °C for 
2 h (in dark), and finally the optical density at 405 nm was 
measured with an ELISA Reader [24]. Caspase-3 activity 
was calculated that confirmed apoptosis as the mechanism 
of cell death. With this data and the value of caspasae-3 
induction by the podophyllotoxin, it was possible to 
calculate the ratio of apoptosis with respect to the positive 
control on murine melanoma cancer cells (B16F10). 
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CONCLUSIONS
In conclusion, a series of fourteen (seven pairs 
of cis- and trans-diastereomers) diversely substituted 
diastereomeric β-lactam derivatives have been 
successfully synthesized. In vitro anticancer evaluation 
showed that one of these newly synthesized cis-β-lactam 
derivatives (6C) possesses higher potency in human 
cervical carcinoma SiHa cell lines, six times higher 
potency in murine melanoma B16F10 cell lines and 
10 times less toxicity in normal liver Chang cell lines 
compared to the positive control colchicine, a well-known 
anticancer alkaloid. Besides the cis-β-lactam 6C, most 
of the newly synthesized β-lactams (both diastereomers) 
exhibited moderate to strong anticancer activity against 
SiHa and B16F10 cancer cell lines. The binding sites of 
the compound on β-tubulin was found to be similar with 
that of colchicine and apoptotic cell death through caspase 
activation was found as the mechanism of action. It was 
supported by the microscopic observation. Molecular 
coupling of the compound 6C on β-tubulin colchicine site, 
exhibited binding interactions with the Cys 239, Lys 252, 
Val 323, Met 257, Lys 350, Leu 246 y Ala 248 amionacid 
residues by molecular docking assay. The molecule 6C 
may find its application in anticancer drug discovery 
process.
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